Synexus builds up presence in Eastern Europe

By Kirsty Barnes

- Last updated on GMT

Related tags: Eastern europe, Europe

The world's largest patient recruitment firm, Synexus Clinical
Research has bagged its first Hungarian company in a bid to exploit
the growing clinical trial opportunities in the emerging Eastern
European market.

Diagnostic Units Hungary (DUH), bought for an initial consideration of €1.5m plus a deferred consideration of €1.25m, is a site management organisation (SMO) based in Budapest, providing clinical trial services, particularly the recruitment and management of patients onto later stage trials.

Late-stage clinical trials are a specialty of Synexus and The Institute of Clinical Research recently presented the founder and director of Synexus, Dr Ian Smith, with the Outstanding Achievement Award, reflecting the company's work in reducing recruitment times and costs in this area.

The UK company, which now has more than 15 centres in five countries, is actively looking to strengthen its multi-country operations through a series of selective acquisitions that centre around its core activity of patient recruitment for late stage trials, with particular focus on the exploitation of growing opportunities for clinical trials and patient recruitment in emerging economies, especially Eastern Europe.

Over the last decade the number of multi-centre clinical trials in the Central and Eastern Europe region has been growing on average at an annual rate of 30 per cent and this growth is expected to continue.

Analysts Frost & Sullivan predict year-on-year growth for the European contract research market of 10.4 per cent up to 2007, when it will be worth an estimated $4.3bn (€3.5bn), primarily driven by the increasing attractiveness of Eastern Europe to drug developers in both the US and Western Europe.

"DUH is a high quality clinic and the major recruiter of patients in Hungary and is in a very exciting position both geographically and strategically,"​ said Michael Fort, chief executive of Synexus, said Fort.

"We will continue to look for similar types of acquisition opportunities over the coming months, with the active encouragement of our clients."

The acquisition is the company's second since joining AIM in November 2005 - in January Synexus bought Polish clinical trials company Skandynawskie Centrum Medyczne (SCM) in a deal that also brought contracts with a number of new customers in the region as well as licences to open further centres in Poland and in neighbouring Ukraine.

The company has also since made its presence known in Bulgaria, opening an office in Sofia.

"The prospects from these centres alone are excellent as they enable the company to offer a pan-European solution to our clients who have significant hubs and head offices in mainland Europe,"​ said Fort.

"Additionally, the centres have varying specialities in their domestic markets allowing us to widen the therapeutic areas offered to our clients."

However, Eastern Europe isn't the company's only focus - late last year Synexus also entered the world's other burgeoning clinical research market, India, setting up the country's first patient-recruitment SMO with IRL, a subsidiary of the Indian Clinical Research Institute.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more